Big Pharma expands its portfolio Earlier this month, Eli Lilly announced detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity, or overweight with a weight-related medical problem and without diabetes
Soffrono di grave insufficienza cardiaca
Oxidized Alkyl Phospholipids Are Specific, High Affinity Peroxisome Proliferator-activated Receptor 3 Ligands and Agonists
The regulator alleges that medicines containing semaglutide, tirzepatide, and combination formulations were being manufactured and distributed outside the legal framework permitted under South African law
PSPeptides offers a pre-formulated CJC-1295/Ipamorelin blend that combines both peptides in a single vial for research convenience, as well as standalone versions of each compound for protocols that require independent dosing
Switching from repression to activation: microRNAs can up-regulate translation
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
